Hans Edgar Bishop's Net Worth
$273 Million
Who is Hans Edgar Bishop?
Hans Edgar Bishop has an estimated net worth of $273 Million. This is based on reported shares across multiple companies, which include AGILENT TECHNOLOGIES, INC., Sana Biotechnology, Inc., Lyell Immunopharma, Inc., Juno Therapeutics, Inc., CELGENE CORP /DE/, AVANIR PHARMACEUTICALS, INC., and DENDREON CORP.
SEC CIK
Hans Edgar Bishop's CIK is 0001480212
Past Insider Trading and Trends
2016 was Hans Edgar Bishop's most active year for acquiring shares with 11 total transactions. Hans Edgar Bishop's most active month to acquire stocks was the month of May. 2016 was Hans Edgar Bishop's most active year for disposing of shares, totalling 26 transactions. Hans Edgar Bishop's most active month to dispose stocks was the month of May. 2010 saw Hans Edgar Bishop paying a total of $1,999,992.88 for 190,533 shares, this is the most they've acquired in one year. In 2018 Hans Edgar Bishop cashed out on 4,082,434 shares for a total of $214,061,666.43, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
AGILENT TECHNOLOGIES, INC. (A) Snapshot price: $137.2
InvestorHans Edgar Bishop owns 24,976.307 units of Common Stock which is worth $3,426,749.32. From 2017 to 2024 Hans Edgar Bishop acquired a total of 24,329.498 shares in AGILENT TECHNOLOGIES, INC. at a cost of $2,389,627.69.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +10.77% | 2.43K |
$147.48 | $358,081.44 | 24.98K |
Mar 15
| |||
Form 4
| +12.01% | 2.4K |
$136.82 | $328,231.18 | 22.38K |
Mar 16
| |||
Form 4
| +14.95% | 2.58K |
$136.82 | $353,269.24 | 19.85K |
Mar 17
| |||
Form 4
| +18.42% | 2.67K |
$121.59 | $324,896.50 | 17.18K |
Mar 18
| |||
Form 4
| +1.24% | 177 |
$93.91 | $16,622.07 | 14.46K |
Aug 3
| |||
Form 4
| +40.59% | 4.11K |
$73.01 | $299,920.97 | 14.23K |
Apr 17
| |||
Form 4
| +52.42% | 3.45K |
$82.00 | $282,935.67 | 10.03K |
Mar 21
| |||
Form 4
| +195.41% | 4.31K |
$67.47 | $291,069.83 | 6.52K |
Mar 22
| |||
Form 4
|
∞
| 2.2K |
$61.21 | $134,600.79 | 2.2K |
Jul 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Sana Biotechnology, Inc. (SANA) Snapshot price: $5.05
InvestorHans Edgar Bishop owns 5,784,551 units of Common Stock which is worth $29,211,982.55. From 2022 to 2024 Hans Edgar Bishop acquired a total of 2,079,551 shares in Sana Biotechnology, Inc..
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
| +0.08% | 4.91K |
—
|
—
| 5.78M |
Jul 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
| +0.05% | 2.77K |
—
|
—
| 5.78M |
Apr 5
| |||
Form 4
| +0.08% | 4.9K |
—
|
—
| 5.78M |
Jan 5
| |||
Form 4
| +0.12% | 6.92K |
—
|
—
| 5.77M |
Oct 5
| |||
Form 4
| +0.07% | 4.15K |
—
|
—
| 5.77M |
Jul 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4
| +0.13% | 7.72K |
—
|
—
| 5.76M |
Apr 5
| |||
Form 4
| +0.12% | 6.7K |
—
|
—
| 5.75M |
Jan 5
| |||
Form 4
| +0.07% | 4.01K |
—
|
—
| 5.75M |
Oct 5
| |||
Form 4
| +0.06% | 3.33K |
—
|
—
| 5.74M |
Jul 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
| +0.05% | 2.88K |
—
|
—
| 5.74M |
Apr 5
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Feb 3
| |||
Form 4
| +54.82% | 2.03M |
—
|
—
| 5.74M |
Feb 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Lyell Immunopharma, Inc. (LYEL) Snapshot price: $1.2
InvestorHans Edgar Bishop owns 4,685,614 units of Common Stock which is worth $5,622,736.80. From 2022 to 2024 Hans Edgar Bishop acquired a total of 1,685,614 shares in Lyell Immunopharma, Inc. at a cost of $113,880.80.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 14
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 16
| |||
Form 4
| +3.20% | 145.38K |
$0.10 | $14,538.00 | 4.69M |
Sep 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4
| +28.01% | 993.43K |
$0.10 | $99,342.80 | 4.54M |
Feb 23
| |||
Form 4
| +18.23% | 546.81K |
—
|
—
| 3.55M |
Jun 21
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Juno Therapeutics, Inc. No price found
CEO & PresidentHans Edgar Bishop used to own units in Common Stock but no longer holds any shares there.acquired a total of 740,246 shares in Juno Therapeutics, Inc. at a cost of $3,776,250.00, Hans also disposed a total of 3,536,355 shares of Juno Therapeutics, Inc. equalling to $240,496,221.55.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -2.45M |
$87.00 |
—
|
0
|
Mar 5
| |||
Form 4
| -4.70% | -120.63K |
$85.49 | -$371,539.54 | 2.45M |
Feb 7
| |||
Form 4
| +2.65% | 66.43K |
—
|
—
| 2.57M |
Jan 31
| |||
Form 4
| -0.97% | -24.50K |
$26.27 | -$10,915,557.89 | 2.5M |
Scheduled
|
Jan 16
| ||
Form 4
| +1.44% | 35.89K |
—
|
—
| 2.53M |
Oct 20
| |||
Form 4
| +1.81% | 44.18K |
—
|
—
| 2.49M |
Feb 7
| |||
Form 4
|
—
|
0
|
$19.68 | -$1,172,160.00 | 2.45M |
Scheduled
|
Sep 27
| ||
Form 4
| -2.83% | -71.25K |
$18.32 | -$2,463,118.19 | 2.45M |
Scheduled
|
Sep 19 - Sep 21
| ||
Form 4
|
—
|
0
|
$18.21 | -$546,030.88 | 2.52M |
Scheduled
|
Sep 8
| ||
Form 4
| -0.96% | -24.50K |
$18.21 | -$1,166,973.80 | 2.52M |
Scheduled
|
Aug 31
| ||
Form 4/A
| -2.73% | -71.25K |
$22.41 | -$4,151,275.75 | 2.54M |
Scheduled
|
Jun 30
| ||
Form 4
| -2.73% | -71.25K |
$22.41 | -$4,151,275.75 | 2.54M |
Scheduled
|
Jun 30
| ||
Form 4
| -1.39% | -36.75K |
$26.39 | -$3,868,904.10 | 2.61M |
Scheduled
|
Jun 9
| ||
Form 4
| -1.37% | -36.75K |
$20.84 | -$2,861,565.36 | 2.65M |
Scheduled
|
Feb 29
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 2
| |||
Form 4
| -1.38% | -37.50K |
$26.04 | -$3,839,971.28 | 2.69M |
Scheduled
|
Dec 15
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
CELGENE CORP /DE/ No price found
InvestorHans Edgar Bishop used to own units in Common Stock but no longer holds any shares there. In the year 2018 Hans Edgar Bishop filed a total of 4 filings.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -23.09K |
—
|
—
|
0
|
Nov 20
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 13
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||